Miromatrix Medical Inc. (MIRO)

NASDAQ: MIRO · IEX Real-Time Price · USD
3.24
-0.26 (-7.31%)
Feb 1, 2023, 11:02 AM EST - Market open
-7.31%
Market Cap 67.63M
Revenue (ttm) 31,115
Net Income (ttm) -28.49M
Shares Out 20.90M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,206
Open 3.47
Previous Close 3.49
Day's Range 3.20 - 3.65
52-Week Range 2.02 - 5.29
Beta n/a
Analysts Buy
Price Target 15.81 (+388.72%)
Earnings Date n/a

About MIRO

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 24, 2021
Employees 61
Stock Exchange NASDAQ
Ticker Symbol MIRO
Full Company Profile

Financial Performance

In 2021, MIRO's revenue was $33,066, a decrease of -28.94% compared to the previous year's $46,530. Losses were -$14.67 million, 42.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for MIRO stock is "Buy." The 12-month stock price forecast is $15.81, which is an increase of 388.72% from the latest price.

Price Target
$15.81
(388.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure

EDEN PRAIRIE, Minn. and DEERFIELD, Ill., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agre...

3 hours ago - GlobeNewsWire

Miromatrix Provides Update on miroliverELAP

EDEN PRAIRIE, Minn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

3 hours ago - GlobeNewsWire

Miromatrix's stock is down 33%

Shares of Miromatrix Medical Inc. were down about 33% in premarket trading on Thursday, the day after the company said there's a clinical hold on its experimental acute liver failure treatment. Miroma...

1 month ago - Market Watch

Miromatrix Announces FDA Clinical Hold on IND Application for miroliverELAP

EDEN PRAIRIE, Minn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

1 month ago - GlobeNewsWire

Miromatrix Announces Participation in the Piper Sandler 34th Annual Healthcare Conference

EDEN PRAIRIE, Minn., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

2 months ago - GlobeNewsWire

Miromatrix Reports Filing of IND, Third Quarter 2022 Results, and Provides Corporate Update

EDEN PRAIRIE, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

2 months ago - GlobeNewsWire

Miromatrix to Report Third Quarter 2022 Financial Results

EDEN PRAIRIE, Minn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

3 months ago - GlobeNewsWire

Miromatrix CEO Jeff Ross Delivering Keynote Address at ARMI | BioFabUSA 2022 Fall Summit: Meeting in the Millyard

EDEN PRAIRIE, Minn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

3 months ago - GlobeNewsWire

Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Mesa

EDEN PRAIRIE, Minn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

4 months ago - GlobeNewsWire

Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

EDEN PRAIRIE, Minn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to ...

4 months ago - GlobeNewsWire

Miromatrix CEO Jeff Ross to Present at the Bioregate European Regenerative Medicine Forum

EDEN PRAIRIE, Minn., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to ...

4 months ago - GlobeNewsWire

Miromatrix Receives New Patent for Its Novel Perfusion Decellularization and Recellularization Technology

EDEN PRAIRIE, Minn., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

5 months ago - GlobeNewsWire

Miromatrix Announces Participation in Upcoming Gilmartin Emerging Growth Company Showcase

EDEN PRAIRIE, Minn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

5 months ago - GlobeNewsWire

Miromatrix Reports Second Quarter 2022 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

6 months ago - GlobeNewsWire

Miromatrix Appoints Jack Lake, M.D., as Medical Director

EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

6 months ago - GlobeNewsWire

Miromatrix to Report Second Quarter 2022 Financial Results

EDEN PRAIRIE, Minn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

6 months ago - GlobeNewsWire

Miromatrix Applauds the FDA for Its Continued Commitment to the Field of Organ Transplant

EDEN PRAIRIE, Minn., July 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to h...

7 months ago - GlobeNewsWire

Miromatrix Announces Participation in the 2022 American Transplant Congress

EDEN PRAIRIE, Minn., May 31, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to he...

8 months ago - GlobeNewsWire

Miromatrix Announces Participation in the 19th Annual Craig-Hallum Institutional Investor Conference

EDEN PRAIRIE, Minn., May 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to he...

8 months ago - GlobeNewsWire

Miromatrix Announces Participation in H.C. Wainwright Global Investment Conference

EDEN PRAIRIE, Minn., May 17, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to he...

9 months ago - GlobeNewsWire

Miromatrix Reports First Quarter 2022 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to he...

9 months ago - GlobeNewsWire

Miromatrix to Report First Quarter 2022 Financial Results

EDEN PRAIRIE, Minn., April 28, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to ...

9 months ago - GlobeNewsWire

Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Med

EDEN PRAIRIE, Minn., April 19, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to ...

10 months ago - GlobeNewsWire

Miromatrix Reports Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., March 30, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to ...

10 months ago - GlobeNewsWire

12 Stocks Halted On A Circuit Breaker This Week

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and br...

11 months ago - Benzinga